The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.
>
12
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
3
